SAMAN HASAN: Open Payments
NPI 1871793893 · APEX, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,218 in 59 payments from 12 companies in 2025. Trend: 2023 $1,028 · 2024 $904 · 2025 $1,218
Food & beverage: $1,218
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 9 | $212 |
| Teva Pharmaceuticals USA, Inc. | 10 | $179 |
| Vanda Pharmaceuticals Inc. | 8 | $163 |
| Lundbeck LLC | 8 | $149 |
| Neurocrine BioSciences, Inc. | 5 | $123 |
| Bausch Health US, LLC | 4 | $79 |
| Otsuka America Pharmaceutical, Inc. | 3 | $69 |
| Axsome Therapeutics, Inc. | 3 | $68 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $64 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $58 |
Products named: REXULTI, VRAYLAR, AUSTEDO XR, HETLIOZ, INGREZZA, WELLBUTRIN, Auvelity, TRINTELLIX.
Industry payments across NC — which companies pay providers there.
